Alibaba's Taobao and Tmall Unveil Growth Plan to Boost Merchant Sales

Monday, Aug 25, 2025 9:27 pm ET1min read

Alibaba's Taobao and Tmall platforms in China are launching a new growth initiative to boost sales. The plan involves investing billions of yuan each month to collaborate with premium merchants through time-limited promotions, including upgraded membership shopping days. Merchants have seen a 10% increase in transaction conversion rates and sales, with 70% of the growth coming from new customers.

Alibaba Group Holding (BABA) is set to launch a new growth initiative to bolster sales on its Taobao and Tmall platforms in China. The initiative involves investing billions of yuan each month to collaborate with premium merchants through time-limited promotions, including upgraded membership shopping days. This strategic move aims to drive sales and attract new customers.

The new initiative has already shown promising results. According to the company, merchants have seen a 10% increase in transaction conversion rates and sales, with 70% of the growth attributed to new customers. This growth is a significant indicator of the potential impact of the new strategy on Alibaba's bottom line.

Alibaba's stock has been performing well, with shares gaining 45% this year and over 50% in the last 12 months. The company is expected to post first-quarter results on August 29, with analysts forecasting net revenue of RMB 253.81 billion ($35.41 billion) and earnings per share of RMB 15.47 [1].

The company's focus on premium merchants and time-limited promotions is a departure from its usual strategy. This shift could help Alibaba tap into new markets and attract more customers, particularly those who are looking for exclusive deals and experiences. The success of this initiative will be closely watched by investors and financial professionals alike.

References:
[1] https://stocktwits.com/news-articles/markets/equity/alibaba-stock-sees-retail-chatter-spike-340-ahead-of-earnings/chssFwcRd1Y

Comments



Add a public comment...
No comments

No comments yet